Peptides for weight

A once-weekly GLP-1 receptor agonist for weight management and metabolic health.

• Significant and sustained weight loss
• Improved blood sugar regulation
• Reduced cardiovascular risk markers

A once-weekly dual GIP and GLP-1 receptor agonist delivering superior weight loss and metabolic improvements compared to GLP-1 monotherapy.

• Greater average weight loss vs. semaglutide
• Improved blood sugar control
• Reduced appetite and cravings

Daily injectable GLP-1 receptor agonist FDA-approved for type 2 diabetes (Victoza, up to 1.8 mg/day) and chronic weight management (Saxenda, up to 3.0 mg/day). Slows gastric emptying, increases satiety, improves glycemic control, and reduces cardiovascular events in T2D.

• Sustained weight loss
• A1C reduction in T2D
• Appetite suppression and reduced food cravings

An orally bioavailable, non-peptide ghrelin receptor agonist that produces sustained increases in GH and IGF-1 with once-daily dosing. Taken as a capsule — no reconstitution needed. Studied for sarcopenia, GH deficiency, and recovery support.

• Sustained 24-hour GH and IGF-1 elevation
• Increased fat-free mass over 12 months
• Improved stage IV and REM sleep quality

A pan-agonist of the estrogen-related receptor (ERR) family — most potent at ERRα — described as an 'exercise mimetic.' Preclinical mouse studies show increased energy expenditure, fatty acid oxidation, and reduced fat mass accumulation.

• Activates aerobic exercise-like gene program (preclinical)
• Increases fatty acid oxidation in mice
• Increases energy expenditure in mice